Effectiveness of Stereotactic Radiotherapy and Bevacizumab for Recurrent High-Grade Gliomas: A Potential Therapy for Isocitrate Dehydrogenase Wild-Type Recurrent High-Grade Gliomas
This study aimed to evaluate the efficacy of stereotactic radiotherapy combined with bevacizumab (SRT-Bv) compared with Bv treatment for recurrent high-grade gliomas (HGGs). Data for patients with recurrent HGGs who received SRT and Bv (n = 29) or Bv (n = 29) between June 2014 and September 2016 wer...
Gespeichert in:
| Veröffentlicht in: | World neurosurgery 2018-06, Vol.114, p.e1138-e1146 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1146 |
|---|---|
| container_issue | |
| container_start_page | e1138 |
| container_title | World neurosurgery |
| container_volume | 114 |
| creator | Yasuda, Takayuki Muragaki, Yoshihiro Nitta, Masayuki Miyamoto, Kazunari Oura, Yuko Henmi, Takuo Noguchi, Sanshiro Oda, Hideaki Saito, Taiichi Maruyama, Takashi Atsuchi, Shoko Miura, Naohisa Kawamata, Takakazu |
| description | This study aimed to evaluate the efficacy of stereotactic radiotherapy combined with bevacizumab (SRT-Bv) compared with Bv treatment for recurrent high-grade gliomas (HGGs).
Data for patients with recurrent HGGs who received SRT and Bv (n = 29) or Bv (n = 29) between June 2014 and September 2016 were retrospectively analyzed. All patients received conventional radiotherapy (total, 60 Gy) before this study. SRT was administered at a median dose of 42 Gy in 3–7 fractions. The recurrence pattern was classified into 3 groups: in-field, marginal, and out-field.
The median overall survival in the SRT-Bv group was significantly longer than that in the Bv group (10.4 vs. 5.6 months; P = 0.02). In patients with isocitrate dehydrogenase wild-type tumors, the SRT-Bv treatment significantly prolonged survival more than the Bv treatment (10.9 vs. 8.2 months; P = 0.01). The World Health Organization grade and presence or absence of SRT were significant prognostic factors in the univariate analysis. Besides brain edema in 2 cases and asymptomatic subdural hematoma in 1 case, no other severe adverse effect due to SRT-Bv treatment was recorded. The pattern of recurrence was as follows: in-field, 2 cases (7%); marginal, 8 cases (28%); out-field, 11 cases (38%); no recurrence on radiologic findings, 6 cases (21%); and uncertain, 2 cases (7%).
SRT-Bv treatment significantly prolonged survival duration more than Bv treatment and provides good local control in patients with recurrent HGGs, especially those with isocitrate dehydrogenase wild-type tumors.
•Stereotactic radiotherapy is a treatment option for high grade glioma.•Combined stereotactic radiotherapy with bevacizumab may prolong survival.•Combined stereotactic radiotherapy with bevacizumab provides local control for recurrent high-grade glioma, especially for the isocitrate dehydrogenase wild-type. |
| doi_str_mv | 10.1016/j.wneu.2018.03.161 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2021729545</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1878875018306430</els_id><sourcerecordid>2021729545</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-e4b438d1984afea7f53c195e72af7db945681a7b652d24cf79648b34a5e51ad3</originalsourceid><addsrcrecordid>eNp9kc1q3DAURk1pSUKaF8iiaNmNXcmS_FO6SdN0Egi0pANdimvpKqPBtqaSPGXyXHnAephpltHmCun7DlxOll0yWjDKqk_r4u-IU1FS1hSUF6xib7Iz1tRN3tRV-_blLulpdhHjms6HM9HU_CQ7LduKCV7Rs-z5xlrUyW1xxBiJt-RXwoA-wfyoyQMY59MKA2x2BEZDvuIWtHuaBuiI9YE8oJ5CwDGRW_e4yhcBDJJF7_wA8TO5Ij99mj8d9GR5pOxbd9FrlwIkJN9wtTPBP-IIEclv15t8udvgq-D32TsLfcSL4zzPlt9vlte3-f2Pxd311X2uuaxSjqITvDGsbQRYhNpKrlkrsS7B1qZrhawaBnVXydKUQtu6rUTTcQESJQPDz7OPB-wm-D8TxqQGFzX2PYzop6hKWrK6bKWQc7Q8RHXwMQa0ahPcAGGnGFV7X2qt9r7U3peiXM2-5tKHI3_qBjQvlf925sCXQwDnJbcOg4ra4ajRuDBLU8a71_j_AFq6ql0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2021729545</pqid></control><display><type>article</type><title>Effectiveness of Stereotactic Radiotherapy and Bevacizumab for Recurrent High-Grade Gliomas: A Potential Therapy for Isocitrate Dehydrogenase Wild-Type Recurrent High-Grade Gliomas</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Yasuda, Takayuki ; Muragaki, Yoshihiro ; Nitta, Masayuki ; Miyamoto, Kazunari ; Oura, Yuko ; Henmi, Takuo ; Noguchi, Sanshiro ; Oda, Hideaki ; Saito, Taiichi ; Maruyama, Takashi ; Atsuchi, Shoko ; Miura, Naohisa ; Kawamata, Takakazu</creator><creatorcontrib>Yasuda, Takayuki ; Muragaki, Yoshihiro ; Nitta, Masayuki ; Miyamoto, Kazunari ; Oura, Yuko ; Henmi, Takuo ; Noguchi, Sanshiro ; Oda, Hideaki ; Saito, Taiichi ; Maruyama, Takashi ; Atsuchi, Shoko ; Miura, Naohisa ; Kawamata, Takakazu</creatorcontrib><description>This study aimed to evaluate the efficacy of stereotactic radiotherapy combined with bevacizumab (SRT-Bv) compared with Bv treatment for recurrent high-grade gliomas (HGGs).
Data for patients with recurrent HGGs who received SRT and Bv (n = 29) or Bv (n = 29) between June 2014 and September 2016 were retrospectively analyzed. All patients received conventional radiotherapy (total, 60 Gy) before this study. SRT was administered at a median dose of 42 Gy in 3–7 fractions. The recurrence pattern was classified into 3 groups: in-field, marginal, and out-field.
The median overall survival in the SRT-Bv group was significantly longer than that in the Bv group (10.4 vs. 5.6 months; P = 0.02). In patients with isocitrate dehydrogenase wild-type tumors, the SRT-Bv treatment significantly prolonged survival more than the Bv treatment (10.9 vs. 8.2 months; P = 0.01). The World Health Organization grade and presence or absence of SRT were significant prognostic factors in the univariate analysis. Besides brain edema in 2 cases and asymptomatic subdural hematoma in 1 case, no other severe adverse effect due to SRT-Bv treatment was recorded. The pattern of recurrence was as follows: in-field, 2 cases (7%); marginal, 8 cases (28%); out-field, 11 cases (38%); no recurrence on radiologic findings, 6 cases (21%); and uncertain, 2 cases (7%).
SRT-Bv treatment significantly prolonged survival duration more than Bv treatment and provides good local control in patients with recurrent HGGs, especially those with isocitrate dehydrogenase wild-type tumors.
•Stereotactic radiotherapy is a treatment option for high grade glioma.•Combined stereotactic radiotherapy with bevacizumab may prolong survival.•Combined stereotactic radiotherapy with bevacizumab provides local control for recurrent high-grade glioma, especially for the isocitrate dehydrogenase wild-type.</description><identifier>ISSN: 1878-8750</identifier><identifier>EISSN: 1878-8769</identifier><identifier>DOI: 10.1016/j.wneu.2018.03.161</identifier><identifier>PMID: 29614360</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Bevacizumab ; Isocitrate dehydrogenase mutation ; Recurrent high-grade glioma ; Stereotactic radiotherapy</subject><ispartof>World neurosurgery, 2018-06, Vol.114, p.e1138-e1146</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-e4b438d1984afea7f53c195e72af7db945681a7b652d24cf79648b34a5e51ad3</citedby><cites>FETCH-LOGICAL-c356t-e4b438d1984afea7f53c195e72af7db945681a7b652d24cf79648b34a5e51ad3</cites><orcidid>0000-0002-2504-6385 ; 0000-0002-5016-9619</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.wneu.2018.03.161$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29614360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yasuda, Takayuki</creatorcontrib><creatorcontrib>Muragaki, Yoshihiro</creatorcontrib><creatorcontrib>Nitta, Masayuki</creatorcontrib><creatorcontrib>Miyamoto, Kazunari</creatorcontrib><creatorcontrib>Oura, Yuko</creatorcontrib><creatorcontrib>Henmi, Takuo</creatorcontrib><creatorcontrib>Noguchi, Sanshiro</creatorcontrib><creatorcontrib>Oda, Hideaki</creatorcontrib><creatorcontrib>Saito, Taiichi</creatorcontrib><creatorcontrib>Maruyama, Takashi</creatorcontrib><creatorcontrib>Atsuchi, Shoko</creatorcontrib><creatorcontrib>Miura, Naohisa</creatorcontrib><creatorcontrib>Kawamata, Takakazu</creatorcontrib><title>Effectiveness of Stereotactic Radiotherapy and Bevacizumab for Recurrent High-Grade Gliomas: A Potential Therapy for Isocitrate Dehydrogenase Wild-Type Recurrent High-Grade Gliomas</title><title>World neurosurgery</title><addtitle>World Neurosurg</addtitle><description>This study aimed to evaluate the efficacy of stereotactic radiotherapy combined with bevacizumab (SRT-Bv) compared with Bv treatment for recurrent high-grade gliomas (HGGs).
Data for patients with recurrent HGGs who received SRT and Bv (n = 29) or Bv (n = 29) between June 2014 and September 2016 were retrospectively analyzed. All patients received conventional radiotherapy (total, 60 Gy) before this study. SRT was administered at a median dose of 42 Gy in 3–7 fractions. The recurrence pattern was classified into 3 groups: in-field, marginal, and out-field.
The median overall survival in the SRT-Bv group was significantly longer than that in the Bv group (10.4 vs. 5.6 months; P = 0.02). In patients with isocitrate dehydrogenase wild-type tumors, the SRT-Bv treatment significantly prolonged survival more than the Bv treatment (10.9 vs. 8.2 months; P = 0.01). The World Health Organization grade and presence or absence of SRT were significant prognostic factors in the univariate analysis. Besides brain edema in 2 cases and asymptomatic subdural hematoma in 1 case, no other severe adverse effect due to SRT-Bv treatment was recorded. The pattern of recurrence was as follows: in-field, 2 cases (7%); marginal, 8 cases (28%); out-field, 11 cases (38%); no recurrence on radiologic findings, 6 cases (21%); and uncertain, 2 cases (7%).
SRT-Bv treatment significantly prolonged survival duration more than Bv treatment and provides good local control in patients with recurrent HGGs, especially those with isocitrate dehydrogenase wild-type tumors.
•Stereotactic radiotherapy is a treatment option for high grade glioma.•Combined stereotactic radiotherapy with bevacizumab may prolong survival.•Combined stereotactic radiotherapy with bevacizumab provides local control for recurrent high-grade glioma, especially for the isocitrate dehydrogenase wild-type.</description><subject>Bevacizumab</subject><subject>Isocitrate dehydrogenase mutation</subject><subject>Recurrent high-grade glioma</subject><subject>Stereotactic radiotherapy</subject><issn>1878-8750</issn><issn>1878-8769</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc1q3DAURk1pSUKaF8iiaNmNXcmS_FO6SdN0Egi0pANdimvpKqPBtqaSPGXyXHnAephpltHmCun7DlxOll0yWjDKqk_r4u-IU1FS1hSUF6xib7Iz1tRN3tRV-_blLulpdhHjms6HM9HU_CQ7LduKCV7Rs-z5xlrUyW1xxBiJt-RXwoA-wfyoyQMY59MKA2x2BEZDvuIWtHuaBuiI9YE8oJ5CwDGRW_e4yhcBDJJF7_wA8TO5Ij99mj8d9GR5pOxbd9FrlwIkJN9wtTPBP-IIEclv15t8udvgq-D32TsLfcSL4zzPlt9vlte3-f2Pxd311X2uuaxSjqITvDGsbQRYhNpKrlkrsS7B1qZrhawaBnVXydKUQtu6rUTTcQESJQPDz7OPB-wm-D8TxqQGFzX2PYzop6hKWrK6bKWQc7Q8RHXwMQa0ahPcAGGnGFV7X2qt9r7U3peiXM2-5tKHI3_qBjQvlf925sCXQwDnJbcOg4ra4ajRuDBLU8a71_j_AFq6ql0</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Yasuda, Takayuki</creator><creator>Muragaki, Yoshihiro</creator><creator>Nitta, Masayuki</creator><creator>Miyamoto, Kazunari</creator><creator>Oura, Yuko</creator><creator>Henmi, Takuo</creator><creator>Noguchi, Sanshiro</creator><creator>Oda, Hideaki</creator><creator>Saito, Taiichi</creator><creator>Maruyama, Takashi</creator><creator>Atsuchi, Shoko</creator><creator>Miura, Naohisa</creator><creator>Kawamata, Takakazu</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2504-6385</orcidid><orcidid>https://orcid.org/0000-0002-5016-9619</orcidid></search><sort><creationdate>201806</creationdate><title>Effectiveness of Stereotactic Radiotherapy and Bevacizumab for Recurrent High-Grade Gliomas: A Potential Therapy for Isocitrate Dehydrogenase Wild-Type Recurrent High-Grade Gliomas</title><author>Yasuda, Takayuki ; Muragaki, Yoshihiro ; Nitta, Masayuki ; Miyamoto, Kazunari ; Oura, Yuko ; Henmi, Takuo ; Noguchi, Sanshiro ; Oda, Hideaki ; Saito, Taiichi ; Maruyama, Takashi ; Atsuchi, Shoko ; Miura, Naohisa ; Kawamata, Takakazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-e4b438d1984afea7f53c195e72af7db945681a7b652d24cf79648b34a5e51ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Bevacizumab</topic><topic>Isocitrate dehydrogenase mutation</topic><topic>Recurrent high-grade glioma</topic><topic>Stereotactic radiotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yasuda, Takayuki</creatorcontrib><creatorcontrib>Muragaki, Yoshihiro</creatorcontrib><creatorcontrib>Nitta, Masayuki</creatorcontrib><creatorcontrib>Miyamoto, Kazunari</creatorcontrib><creatorcontrib>Oura, Yuko</creatorcontrib><creatorcontrib>Henmi, Takuo</creatorcontrib><creatorcontrib>Noguchi, Sanshiro</creatorcontrib><creatorcontrib>Oda, Hideaki</creatorcontrib><creatorcontrib>Saito, Taiichi</creatorcontrib><creatorcontrib>Maruyama, Takashi</creatorcontrib><creatorcontrib>Atsuchi, Shoko</creatorcontrib><creatorcontrib>Miura, Naohisa</creatorcontrib><creatorcontrib>Kawamata, Takakazu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>World neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yasuda, Takayuki</au><au>Muragaki, Yoshihiro</au><au>Nitta, Masayuki</au><au>Miyamoto, Kazunari</au><au>Oura, Yuko</au><au>Henmi, Takuo</au><au>Noguchi, Sanshiro</au><au>Oda, Hideaki</au><au>Saito, Taiichi</au><au>Maruyama, Takashi</au><au>Atsuchi, Shoko</au><au>Miura, Naohisa</au><au>Kawamata, Takakazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of Stereotactic Radiotherapy and Bevacizumab for Recurrent High-Grade Gliomas: A Potential Therapy for Isocitrate Dehydrogenase Wild-Type Recurrent High-Grade Gliomas</atitle><jtitle>World neurosurgery</jtitle><addtitle>World Neurosurg</addtitle><date>2018-06</date><risdate>2018</risdate><volume>114</volume><spage>e1138</spage><epage>e1146</epage><pages>e1138-e1146</pages><issn>1878-8750</issn><eissn>1878-8769</eissn><abstract>This study aimed to evaluate the efficacy of stereotactic radiotherapy combined with bevacizumab (SRT-Bv) compared with Bv treatment for recurrent high-grade gliomas (HGGs).
Data for patients with recurrent HGGs who received SRT and Bv (n = 29) or Bv (n = 29) between June 2014 and September 2016 were retrospectively analyzed. All patients received conventional radiotherapy (total, 60 Gy) before this study. SRT was administered at a median dose of 42 Gy in 3–7 fractions. The recurrence pattern was classified into 3 groups: in-field, marginal, and out-field.
The median overall survival in the SRT-Bv group was significantly longer than that in the Bv group (10.4 vs. 5.6 months; P = 0.02). In patients with isocitrate dehydrogenase wild-type tumors, the SRT-Bv treatment significantly prolonged survival more than the Bv treatment (10.9 vs. 8.2 months; P = 0.01). The World Health Organization grade and presence or absence of SRT were significant prognostic factors in the univariate analysis. Besides brain edema in 2 cases and asymptomatic subdural hematoma in 1 case, no other severe adverse effect due to SRT-Bv treatment was recorded. The pattern of recurrence was as follows: in-field, 2 cases (7%); marginal, 8 cases (28%); out-field, 11 cases (38%); no recurrence on radiologic findings, 6 cases (21%); and uncertain, 2 cases (7%).
SRT-Bv treatment significantly prolonged survival duration more than Bv treatment and provides good local control in patients with recurrent HGGs, especially those with isocitrate dehydrogenase wild-type tumors.
•Stereotactic radiotherapy is a treatment option for high grade glioma.•Combined stereotactic radiotherapy with bevacizumab may prolong survival.•Combined stereotactic radiotherapy with bevacizumab provides local control for recurrent high-grade glioma, especially for the isocitrate dehydrogenase wild-type.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29614360</pmid><doi>10.1016/j.wneu.2018.03.161</doi><orcidid>https://orcid.org/0000-0002-2504-6385</orcidid><orcidid>https://orcid.org/0000-0002-5016-9619</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1878-8750 |
| ispartof | World neurosurgery, 2018-06, Vol.114, p.e1138-e1146 |
| issn | 1878-8750 1878-8769 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2021729545 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Bevacizumab Isocitrate dehydrogenase mutation Recurrent high-grade glioma Stereotactic radiotherapy |
| title | Effectiveness of Stereotactic Radiotherapy and Bevacizumab for Recurrent High-Grade Gliomas: A Potential Therapy for Isocitrate Dehydrogenase Wild-Type Recurrent High-Grade Gliomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A01%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20Stereotactic%20Radiotherapy%20and%20Bevacizumab%20for%20Recurrent%20High-Grade%20Gliomas:%20A%20Potential%20Therapy%20for%20Isocitrate%20Dehydrogenase%20Wild-Type%20Recurrent%20High-Grade%20Gliomas&rft.jtitle=World%20neurosurgery&rft.au=Yasuda,%20Takayuki&rft.date=2018-06&rft.volume=114&rft.spage=e1138&rft.epage=e1146&rft.pages=e1138-e1146&rft.issn=1878-8750&rft.eissn=1878-8769&rft_id=info:doi/10.1016/j.wneu.2018.03.161&rft_dat=%3Cproquest_cross%3E2021729545%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2021729545&rft_id=info:pmid/29614360&rft_els_id=S1878875018306430&rfr_iscdi=true |